Pelthos Therapeutics has launched “Moms Against Molluscum,” a caregiver-focused movement and website designed to elevate awareness of molluscum contagiosum...

Beghou has launched ARC, a connected commercialization platform designed to unify data, technology, and field execution into a single...

Gelteq has signed a product development and profit‑sharing agreement with Melbourne Health, operator of the Royal Melbourne Hospital, to...

Rein Therapeutics has secured authorization from the European Medicines Agency to initiate the Phase 2 RENEW trial of LTI-03...

Assembly Biosciences reported interim Phase 1b results for its long-acting HSV helicase-primase inhibitor ABI-5366, presented as a late-breaking oral...

60 Degrees Pharmaceuticals will initiate B-FREE, a Phase 2 open-label study of tafenoquine (marketed as Arakoda for malaria prophylaxis)...

FDA has approved Lasix Onyu, a subcutaneous, high‑concentration furosemide drug–device combination for treating edema due to fluid overload in...

Boehringer Ingelheim has secured FDA approval for Jascayd (nerandomilast), an oral, first-in-class preferential PDE4B inhibitor for adults with idiopathic...

Novo Nordisk has agreed to acquire Akero Therapeutics for $54 per share in cash, or roughly $4.7 billion at...

Nilo Therapeutics has closed a $101 million Series A and named Kim Seth as chief executive officer and board...